<<<THE MORNING READ-- ALL THE NEWS WORTH INGESTING -->>> Hey folks we had a major rain situation. People are dead in NYC basement apartments. Danbury Ct got 8 inches. Yonkers is flooded. Ct rivers are swelled, my Kirby Brook had the howl of a jet engine it was really scary last night. We had blinking lights and very brief power outage so grateful for that. What a terrible summer of wet weather. There has been some drama with our friend The Brother-In-Law Stockbroker he may of been in a life threatening situation last night at 3:00 in the morn, or some other situation, I have not got the details yet. More to come. Quanta Services to acquire Blattner Holding for $2.7B 07:04 PWR Van I believe Quanta is an investment of yours, this sounds like a ridiculous amount to pay for some Minn company but upon closer examination these Blattner cats make a ton of dough in the renewable space<--- Materialise initiated with a Buy at Stifel 06:46 MTLS? Never heard of the company but I like the name. Cathie Wood's ARK Investment bought about 382K shares of Pfizer on Wednesday 06:42 PFE Won't it be funny when they come with the white coats and take Cathie away... that she had escaped from some facility... On sale Dept- Last year Van went short Olly at $100 and boy was he right -it dropped then. Recovered and now dripped again! Ollie's shares attractive at current levels, says Piper Sandler 06:39 OLLI Piper Sandler analyst Peter Keith reiterates an Overweight rating on Ollie's Bargain Outlet with a $90 price target after hosting meetings with management. The analyst sees "negatives and positives," but ultimately views the shares as attractive at current levels. To the negative, the Q2 comp suggests Ollie'sis not a structural Covid winner and cost pressures from freight and wages will persist into 2022, Keith tells investors in a research note. But to the positive, the company is guiding for sequential comp improvement, its long-term annual store growth of 50-55 remains intact, and the closeout environment is healthy and should accelerate meaningfully in 2022, says the analyst. RumbleON initiated with an Outperform at Baird 06:35 RMBL- Another co I am not familiar with but Great Name! I think it's tech. Deutsche Bank starts Blade Air Mobility with Buy rating, $15 target 06:33 BLDE I like these guys too but wicked SPAC. Vice Media raises $85M as SPAC negotiations fall through, The Information says 06:30 VII Vice Media is raising more than $85M in fresh financing from current investors as discussions to go public through a special purpose acquisition company have fell through, The Information's Jessica Toonkel reports, citing people familiar with the situation. The company had been looking to raise funds by going public via a SPAC backed by 7GC & Co., but a delay in the once-booming SPAC market has ended those negotiations for now. Girlfriend are you crazy Pt 1- Star stock-picker Cathie Wood buys the Zoom dip, invests over $56 million Girlfriend are you crazy Pt 2? Dept- Jessica Simpson to Buy Her Name From Bankruptcy for $65 Million NOBODY CARES ANYMORE!
Morning Stoney, I think Vice, Buzzfeed and Huffington Post are looking for more cash. Vice had more layoffs this week providing no warning. Who would invest after HBO lost their ass?
We have been watching this Covid Anti-Body Play with interest-- it zoomed to $1.00 and it stuck there it did not retrace, perhaps a sign that it wants to go higher. Starting a trial really is not big news- stk is up 5% but it's word of that trial, when we get a whiff on interim data, if it's positive this stock is off to the moon. Is it worth a shot here... I'd be careful.... Rather pick this up end of month when no one is paying attention.... But lets focus anyway on ADMP<--- Been at this $1.05 level<---- Adamis gets dosing underway in phase 2/3 Tempol COVID-19 trial Sep. 02, 2021 7:42 AM ETAdamis Pharmaceuticals Corporation (ADMP) Adamis Pharmaceuticals (NASDAQ:ADMP)starts dosingpatients in its Phase 2/3 trial testing Tempol in adult patients with confirmed COVID-19 infection. The trial, which is designed to enroll 248 patients, has a primary endpoint of rate of hospitalization for patients receiving Tempol, versus those receiving placebo. As part of the initial Phase 2 portion of the study, 50 COVID positive subjects will be enrolled and randomized 1:1 to receive either Tempol or placebo. An interim analysis by the data and safety monitoring board (DSMB) will examine safety and markers of systemic inflammation during a Stage 1 interim analysis. Based on the DSMB analysis, the Phase 3 portion of the trial designed to enroll 198 patients may begin, with a second interim analysis planned after enrollment of 124 patients. Shares up more than 5% premarket.<------ Related news: The World Health Organization said a strain of the coronavirus that causes COVID-19 and that was first detected in Colombia in January has become a “variant of interest” and will be closely monitored for signs it is resistant to the vaccines that have been authorized for use so far. In its weekly epidemiological update, the agency said the variant, B.1.621, to which it has assigned the Greek letter mu, has “a constellation of mutations that indicate potential properties of immune escape.” Also) **Baxter to buy medical equipment maker Hillrom for $10.5 billion in cash
When The WHO finds a " variant of interest " run for the hills. That's their code talk for we got a problem.... ADMP- $1.14<----- I'm waiting for $1.08
It was scary Van. The noise was equal to a large plane. Listen: FARM coffee let me know & Rover Group, Inc. (ROVR) NasdaqGM - NasdaqGM Real Time Price. Currency in USD $12.40+0.78 (+6.71%)-- At close: September 1 4:00PM EDT-- Description Rover Group, Inc. operates an online marketplace for pet care worldwide. It connects pet parents with pet providers who offer overnight services, including boarding and in-home pet sitting, as well as daytime services, such as doggy daycare, dog walking, drop-in visits, and grooming. The company was incorporated in 2011 is based in Seattle, Washington. Rover initiated with Outperform on strong retention at William Blair 08/26 ROVR William Blair analyst Ralph Schackart initiated coverage of Rover Group with an Outperform rating and no price target. Rover's platform has continually driven strong retention among both pet owners and pet care providers, with over 90% revenue retention from pet care providers between year one and year two on the platform, Schackart tells investors in a research note. The analyst says the company excels at maintaining a steady stream of new supply and demand, with 67% of pet parents coming to the platform after previously using pet care services only from friends, family, or neighbors.
Atai Life Sciences Atai Life Sciences N.V. (ATAI) is psychedelic medicine's largest company, by market value. Debuting on the Nasdaq exchange earlier this year, the company owns or operates or both 10 different companies developing a variety of psychedelic and non-psychedelic medicines. Atai is the most well-funded company in the industry and is backed by big name investors. Florian Brand is the co-founder and chief executive officer of Atai Life Sciences and an entrepreneur. Co-founder and chairman Christian Angermayer is also a major part of the executive leadership team.